Brief: Abbisko Cayman Says EGFR Exon20ins Inhibitor Absk112 Received Clinical Trial Approval From FDA
04/07/2023 11:29
July 4 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* EGFR EXON20INS INHIBITOR ABSK112 RECEIVED CLINICAL TRIAL
APPROVAL FROM FDA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly